Related references
Note: Only part of the references are listed.Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations
Marina Grandis et al.
HUMAN MOLECULAR GENETICS (2008)
Diabetes mellitus exacerbates motor and sensory impairment in CMT1A
Soham Sheth et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
Charcot-Marie-Tooth neuropathies: Diagnosis and management
Agnes Jani-Acsadi et al.
SEMINARS IN NEUROLOGY (2008)
Stoichiometric alteration of PMP22 protein determines the phenotype of hereditary neuropathy with liability to pressure palsies
Jun Li et al.
ARCHIVES OF NEUROLOGY (2007)
Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy
Gerd Meyer zu Horste et al.
ANNALS OF NEUROLOGY (2007)
Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie- Tooth neuropathy 1B
A. Sabet et al.
NEUROLOGY (2006)
Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease
LH Weimer et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside
J Li et al.
BRAIN (2005)
Reliability and validity of the CMT neuropathy score as a measure of disability
ME Shy et al.
NEUROLOGY (2005)
IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy
R Lombardi et al.
ANNALS OF NEUROLOGY (2005)
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
E Passage et al.
NATURE MEDICINE (2004)
Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies
J Li et al.
MUSCLE & NERVE (2004)
Peripheral myelin protein 22 kDa and protein zero:: domain specific trans-interactions
B Hasse et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2004)
Quantification of myelinated endings and mechanoreceptors in human digital skin
M Nolano et al.
ANNALS OF NEUROLOGY (2003)
Phenotypic differences between peripheral myelin protein-22 (PMP22) and myelin protein zero (P0) mutations associated with Charcot-Marie-Tooth-related diseases
I Shames et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)
MW Sereda et al.
NATURE MEDICINE (2003)
The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes
K Inoue et al.
GENOME RESEARCH (2001)
Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A
KM Krajewski et al.
BRAIN (2000)
Share Paper
